FDA Approves Adjuvant Atezolizumab for Select Stage II to IIIA NSCLC | OncLive
The FDA has approved atezolizumab for use as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer whose tumors have...
onclive.com